Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine

Authors

  • Chinedum Peace BABALOLA

Keywords:

caffeine, halofantrine, physicochemical interaction

Abstract

Halofantrine (Hf) is a poorly water-soluble drug for treating malaria in endemic areas like tropical Africa, where caffeine-containing products are habitually consumed. Previous reports showed that caffeine increased the aqueous solubility of Hf at room temperature over 3 days. The aim of this study was to determine the effect of caffeine and caffeine- containing beverages on dissolution and solubility of Hf and to investigate any possible interactions. The aqueous solubility and dissolution of Hf alone and in the presence of caffeine was investigated at pH 1.3, 5.9 and 7.4 using standard methods. The solubility of Hf in the presence of aqueous extracts of cocoa, coffee, black tea and green tea at pH 5.9 was also investigated. In 1 hour, caffeine markedly increased the aqueous solubility of Hf at pH 1.3, 5.9 and 7.4. Caffeine and caffeine-containing beverages markedly increased the aqueous solubility of Hf by between 100- to more than 1600- fold, with a 1672-fold increase by caffeine (from 76.6 ±7.8 ng/mL to128.2 ± 4.5 mg/mL) at pH 5.9. The dissolution of Hf tablets at pH 1.3, 5.9 and 7.4 showed the respective amounts released as 3.57 ± 0.09, 0.95 ± 0.19 and 0.260 ± 0.043 mg, but introduction of caffeine increased these values to 9.51 ± 0.23, 3.70 ± 0.12 and 0.52 ± 0.10 mg respectively, representing 3-fold, 4-fold and 2-fold respectively. These results prove physico-chemical interaction between caffeine and halofantrine. The consequence of this finding is unknown but may affect malaria chemotherapy when Hf is administered concurrently with caffeine-containing products.

How to Cite

Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. (2014). Global Journal of Medical Research, 14(3), 5-10. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Author Biography

Chinedum Peace BABALOLA

Chinedum Peace Babalola is a Professor of Pharmaceutical Chemistry and Pharmacokinetics at, University of Ibadan (UI), Nigeria. She is the immediate past vice-chancellor of Chrisland University, Abeokuta, Nigeria (2017-2024). She is a past Dean of the Faculty of Pharmacy, UI (2013-2017), past Head of the Department of Pharmaceutical Chemistry, and past Director of General Studies, UI. She earned her B.Pharm, MSc, and PhD in Pharmaceutical Chemistry (Pharmacokinetics) from Obafemi Awolowo University, Ife, Nigeria; a Postdoctoral Fellowship at University of British Columbia, Canada, Doctor of Pharmacy (PharmD) from University of Benin, Nigeria; a Postgraduate Diploma in Industrial Pharmacy and technology (IPAT) from Kilimanjaro School of Pharmacy Tanzania/Purdue University, USA, and an Executive Management Certificate from Lagos Business School, Pan Atlantic University, Lagos, Nigeria. Her illustrious career is marked by historic milestones: the first female Professor and Dean of Pharmacy at the University of Ibadan, the first Nigerian female inducted Fellow of the African Academy of Sciences (FAAS), the first female Nigerian pharmacist inducted Fellow of the Academy of Science (FAS) as well as Vice-Chancellor, where she led Chrisland University with remarkable distinction for seven years. Professor Babalola’s research spans over four decades, focusing on pharmacokinetics, pharmacogenetics, Clinical trials, Biopharmaceutics (BA-BE), Biomedical research, and drug development. Her work has provided vital insights into the treatment of malaria, HIV/AIDS, sickle cell disease, and cancer in African populations. She has conducted landmark pharmacogenetic studies in Nigerians, explored breast cancer genomics, applied machine learning in drug discovery, and holds two patents. Her collaborative spirit has united pharmacists, physicians, and scientists in advancing precision medicine and public health. She has served as an Honorary Consultant at University College Hospital (UCH), Ibadan, since 2015. As a multi-grant awardee, she led the establishment of the Centre for Drug Discovery, Development and Production (CDDDP), University of Ibadan, in 2012 by an approximately $1 million MacArthur grant, which has advanced medicine regulation, drug discovery, and capacity building across Africa. She directed the Centre from 2012 to 2017. It also developed pharmaceutical products used during health emergencies such as the Ebola and COVID-19 pandemics. Other grants include NIH, TWAS, Tetfund, GSK, Pfizer, ADA, among others. Her leadership extended nationally as founding Chair of the PSN Deans’ Forum, where she contributed to the approval of the Doctor of Pharmacy (PharmD) program in Nigeria Her numerous accolades include the winner of, African Union Kwame Nkrumah Regional Prize for Scientific Excellence, the May & Baker prize for Best Pharmacist in Nigeria, and the WIMBIZ Five Female Academic Achievers Award in Nigeria. Professor Babalola has mentored hundreds of young professionals and researchers now in leadership worldwide. She has authored close to 120 peer-reviewed publications, presented at more than 150 conferences, and holds two patents. She is a Fellow of seven academies, including the Nigerian Academy of Science (FAS), the African Academy of Sciences (FAAS), the Pharmaceutical Society of Nigeria (FPSN), Nigeria Academy of Pharmacy (FNAPharm), the West African Postgraduate College of Pharmacists (FPCPharm), the Institute of Public Analysts of Nigeria (FIPAN), and, Academy of Medical Sciences (FAMeds).

References

C. Babalola, A. Adegoke, M. Ogunjimi, M. Osimosu (2003) Determination of physicochemical properties of halofantrine Afr J Med Med Sci. 32(4), 357-359.

L. Schmidt, Ruth Crosby, Jane Rasco, Dennis Vaughan (1978) Antimalarial activities of various 9- phenanthrenemethanols with special attention to WR-122,455 and WR-171,669 Antimicrob Agents Chemother. 14(3), 292-314. https://doi.org/10.1128/aac.14.3.292

G. Childs, C. Lambros, J. Notsch, C. Pamplin, D. Davidson, A. Ager (1984) Comparison of in vitro and in vivo antimalarial activities of 9- phenanthrenecarbinols. 78(1), 13-20.

W. Watkins, J. Lury, D. Kariuki, D. Koech, J. Oloo, M. Mosoba, M. Mjomba, H. Gilles (1988) Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya. 2(8605), 247-50.

F. ter Kuile, F. Nosten, T. Chongsuphajaisiddhi, N. White, G. Dolan, C. Luxemburger, L. Phaipun, M. Edstein, H. Webster (1993) Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. 341(8852), 1044-9.

E. Boudreau, L. Pang, K. Dixon, H. Webster, K. Pavanand, L. Tosingha, P. Somutsakorn, C. Canfield (1988) Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand Bull World Health Organ. 66(2), 227-235.

Bryson HM, Goa KL (1992) Halofantrine A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential Drugs. 43(2), 236-258.

K. Milton, G. Edwards, S. Ward, M. Orme, A. Breckenridge (1989) Pharmacokinetics of halofantrine in man: effects of food and dose size. 28(1), 71-7.

Sylvester Aideloje, Cyprian Onyeji, Nicholas Ugwu (1998) Altered Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate Eur J Pharm Biopharm. 46(3), 299-303. https://doi.org/10.1016/s0939-6411(98)00029-0

Bassi PU, Onyeji CO, Ukponmwan OE (2004) Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. 58(1), 52-5.

Lee-Yong Lim, Mei-Lin Go (2000) Caffeine and nicotinamide enhances the aqueous solubility of the antimalarial agent halofantrine. 10(1), 17-28. https://doi.org/10.1016/s0928-0987(99)00084-6

Yetunde Kolade, Chinedum Babalola, Ajibola Olaniyi, Gerhard Scriba (2008) Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine Eur J Clin Pharmacol. 64(1), 77-81. https://doi.org/10.1007/s00228-007-0387-0

Kolade YT, Babalola CP, Scriba GK (2006) Analysis of the antimalarial drug halofantrine and its major metabolite N-desbutylhalofantrine in human plasma by high performance liquid chromatography. 41(1), 315-9.

T. Tanaka, A. Okayama, S. Seguchi, M. Ohhashi, S. Tahara, M. Tamaki (2000) Contents of caffeine, theobromine and theophylline in favorite foods Nara Prefect Inst Public Health, Nara, Japan. 34, 71-73.

Cosgriff TM, Boudreau EF, Pamplin CL, Doberstyn EB, Desjardins RE, Canfield CJ (1982) Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669). 31(6), 1075-9.

W. Colwell, V. Brown, P. Christie, J. Lange, C. Reece, K. Yamamoto, D. Henry (1972) Antimalarial arylaminopropanols. 15(7), 771-5.

E. Monlun, O. Pillet, J. Cochard, Favarel Garrigues, J., Le Bras, M. (1993) Prolonged QT interval with halofantrine. 341(8859), 1541-1542.

M. Fawzi, E. Davison, M. Tute (1980) Rationalization of drug complexation in aqueous solution by use of Hückel frontier molecular orbitals. 69(1), 104-6.

Rasool AA, Hussain AA, Dittert LW (1991) Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds. 80(4), 387-93.

S. Carter (1972) Carter SJ, Cooper and Gunn's Dispensing for Pharmaceutical Students. 10.

Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine

Published

2014-01-27

How to Cite

Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. (2014). Global Journal of Medical Research, 14(3), 5-10. https://medicalresearchjournal.org/index.php/GJMR/article/view/